NEW YORK – In a paper published in the Journal of Clinical Oncology last month, researchers zoomed in on a cohort from a Phase I open-label dose escalation and expansion study of ivosidenib (Agios' Tibsovo) and reported that the drug may have activity in IDH1-mutated chondrosarcoma patients.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.